RJA
AVEO

Raymond James & Associates’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Raymond James & Associates’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-3,330
Closed -$21K – 3831
2019
Q4 		$21K Sell
3,330
-100
-3% -$736 ﹤0.01% 3611
2019
Q3 		$29K Buy
3,430
+2,000
+140% +$14.9K ﹤0.01% 3517
2019
Q2 		$10K Buy
1,430
+150
+12% +$1.28K ﹤0.01% 3588
2019
Q1 		$10K Sell
1,280
-150
-10% -$1.55K ﹤0.01% 3570
2018
Q4 		$23K Buy
1,430
+410
+40% +$9.02K ﹤0.01% 3427
2018
Q3 		$34K Buy
+1,020
New +$26.2K ﹤0.01% 3514

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
XSC
X-Square Capital Guaynabo, Puerto Rico $297M AUM 32.87% 1-Year Est. Return
WG
Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Raymond James & Associates's AVEO Position: Q1 2020 in Review

Raymond James & Associates sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2020, closing a stake of 3,330 shares — an estimated $21K sold.

Raymond James & Associates first reported a position in AVEO in Q3 2018 and held it in 6 quarters. The position peaked at $34K in Q3 2018. 35 funds tracked by Wall St. Rank hold AVEO as of Q1 2020.

  • Raymond James & Associates reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • Raymond James & Associates sold 3,330 AVEO Pharmaceuticals, Inc. shares in Q1 2020, an estimated $21K.
  • Raymond James & Associates first reported a position in AVEO Pharmaceuticals, Inc. in Q3 2018 and held it in 6 quarters.
  • Raymond James & Associates's AVEO Pharmaceuticals, Inc. position peaked at $34K in Q3 2018.
  • 35 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2020.

Based on Raymond James & Associates's 13F filing for Q1 2020, filed 21 Apr 2020.